ACHL Stock Overview
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Achilles Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.81 |
| 52 Week High | US$1.76 |
| 52 Week Low | US$0.74 |
| Beta | 1.09 |
| 1 Month Change | -25.95% |
| 3 Month Change | -1.43% |
| 1 Year Change | -9.40% |
| 3 Year Change | -94.91% |
| 5 Year Change | n/a |
| Change since IPO | -95.08% |
Recent News & Updates
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?
Feb 26
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation
Nov 13Recent updates
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?
Feb 26Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation
Nov 13Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation
Jul 19Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?
Mar 11Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation
Nov 18Achilles-led group gets €4M funding for personalized cell therapy manufacturing
Jul 21Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?
Apr 13Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans
Dec 27Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation
Sep 09Shareholder Returns
| ACHL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.6% | -4.2% | -3.7% |
| 1Y | -9.4% | -2.0% | 20.5% |
Return vs Industry: ACHL underperformed the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: ACHL underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| ACHL volatility | |
|---|---|
| ACHL Average Weekly Movement | 13.8% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ACHL's share price has been volatile over the past 3 months.
Volatility Over Time: ACHL's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 210 | Iraj Ali | www.achillestx.com |
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company’s lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021.
Achilles Therapeutics plc Fundamentals Summary
| ACHL fundamental statistics | |
|---|---|
| Market cap | US$32.96m |
| Earnings (TTM) | -US$69.66m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs ACHL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACHL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$69.67m |
| Earnings | -US$69.66m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.70 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ACHL perform over the long term?
See historical performance and comparison